Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Latest executive order in spree to control biopharma centers on American-made drug products

Executive order mandates essential medicines and ingredients be purchased from U.S. sources

An “America first” drug sourcing order signed Thursday is the latest in a series of attempts by President Donald Trump to bend the biopharma industry to his will in an effort to keep campaign promises to lower drug prices and bring manufacturing back to the U.S.

The executive order is the Trump administration’s fifth in the past two weeks targeting biopharma, and comes after industry CEOs boycotted a July White House meeting following the rollout of four drug pricing initiatives, including an international reference pricing scheme for biologics.

PhRMA president and CEO Stephen Ubl said in a

Read the full 969 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers